Novel Coronavirus Information Center
Elsevier’s free health and medical research on novel coronavirus (2019-nCoV)
Welcome to Elsevier's Novel Coronavirus Information Center. Here you will find expert, curated information for the research and health community on Novel Coronavirus (also referred to as COVID-19 and its temporary title 2019-nCoV). All resources are free to access and include guidelines for clinicians and patients. Under the 'Research' tab you will find the latest early stage and peer-reviewed research from journals including The Lancet and Cell Press, as well as a link to the Coronavirus hub on ScienceDirect, where you will find every article relevant article to Coronavirus, SARS, and MERS freely available. Under the Clinical Solutions tab you will find resources for nurses, clinicians and patients, including FAQs on symptoms.
Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier
Recent events have shown us (again) how rapidly a new disease can take root and spread. Such events are accompanied by an explosion of clinical and epidemiological information and research. The goal of this website is to open whatever resources we can to help public health authorities, researchers and clinicians contain and manage this disease. We will provide continually updated resources from Elsevier's content and experts. Our resources span scientific and medical journals and textbooks, educational products, and a variety of other resources, like travel precautions from the CDC and media posts of interest to our community. We have also created a interactive global map of experts based on Scopus data.
The site is curated by clinical experts from our Global Health business and updated frequently to keep pace with evolving knowledge.
Elsevier, Cell Press and The Lancet have also joined the signatories on the Wellcome Trust’s Statement designed to ensure that research findings and data relevant to this outbreak are shared rapidly and openly to inform the public health response and help save lives.
If you're looking for information on our other free and low-cost access programs, including resources for patients and caregivers, you can find that here.
Expert guidance and commentary
COVID-19: Seeking reliable information amid uncertainty
By Ian Chuang, MD, Chief Medical Officer, Elsevier
Medicine is continuously evolving in terms of refining, revising and discovering new knowledge. This is heightened in importance and compressed in timeframe during a crisis such as the current viral outbreak of the COVID-19.
The COVID-19 that originated in Wuhan, China, has exceeded more than 71,000 confirmed cases and over 1,700 deaths since the first case was detected in December 2019. As of February 18, the number of confirmed cases in Singapore has risen to 77. The World Health Organization (WHO) has termed this current epidemic as a global emergency, and it is a public health responsibility at a massive scale.
Accelerating Knowledge-based scientific research
Knowledge is being discovered every day, and the acquisition of it needs to continue to be validated by evidence-based processes in order to ensure its credibility and usability. A study published on medRxiv has found that the incubation period for the virus in rare cases is as long as 24 days compared to the previously believed 14 days. This was concluded from one patient who reported a 24-day incubation period. Researchers have also found another early identification method which involves using CT scans as the key basis for diagnosing coronavirus infections. However, this diagnostic method was developed from the shortage of test kits and has not been peer-reviewed. Thus it should not be used to guide clinical practice.
This highlights the need to share and review data to validate the reliability of new knowledge so that researchers and scientists who are racing against time can be reassured when determining diagnostics and treatment methods for the patients. In Thailand and here in Singapore, doctors are treating a small number of patients with a cocktail of flu and HIV drugs to test for the efficacy of this combination of medications. While there are promising outcomes from these trials, more extensive research and investigation needs to be conducted to determine if they can be used as a standard form of treatment.
After harnessing the knowledge from scientific research backed by evidence-based processes, it needs to be made readily accessible to the public and healthcare professionals on the front line of patient care in order to provide guidance as to what to communicate, what to look for and what to do. Knowledge is constantly evolving and is only as good as when it can be applied as needed.
Seeking open and trusted communication channels
The proliferation of social media platforms has fueled uncertainty among the public. Chinese officials have started blocking and disabling social media accounts to maintain social stability amid the crisis. In such times, the public should turn to trusted traditional and credible communication channels. Resources from the WHO, the Ministry of Health and Gov.sg websites allow the public to dispel fake news and receive updates on the latest and most credible information.
Healthcare professionals can overcome the uncertainty about the virus through accessing medical knowledge via clinical resources such as clinical decision support (CDS) tools or research platforms. These platforms have routinely served their needs and are stepping up more to provide more clarity on the prognosis during this epidemic situation. With timely access to the latest clinical research and guidelines integrated with healthcare professionals’ workflows, better guidance can be provided to patients at the point-of-care. A quick analysis of the search activity done on the CDS showed that in times of uncertainty, clinicians turn to these clinical resources for trusted medical knowledge.
Facilitating the free flow of information
The multitude of digital platforms allow for information to be published and distributed freely. Healthcare professionals need the convenience of seeking out credible research information on one consolidated platform. Medical journals including JAMA Network and The Lancet, and STM publishers including Elsevier, have created their own free-to-access resource centers curated by global health experts to assist health professionals in their research and practice to help draw a close to this outbreak. We also host resources in the Chinese language to support healthcare professionals in China with the latest information and research on the COVID-19.
While we know very little about this current epidemic, scientists and researchers around the world are doing their best to discover new knowledge every day to accelerate scientific research and treatment methods to curb and control the epidemic spread. It is vital that this knowledge is freely shared and widely accessed by both the healthcare professionals and the general public to minimize the impact of this outbreak.
JAMA Medical News Podcast: Coronavirus and Beyond: Responding to Biological Threats
The 2019 novel coronavirus outbreak exemplifies ongoing biothreats to global security, as each new threat tests principles of preparation and response at national, regional, and clinical levels. Tom Inglesby, MD, director of the Center for Health Security at the Johns Hopkins Bloomberg School of Public Health, discusses biosecurity with Angel Desai, MD, JAMA Fishbein fellow. Listen to the interview
6 of the most common coronavirus questions the media is asking
By Rodney E. Rohde, PhD, Professor and Chair, Clinical Laboratory Program, Texas State University | Feb 6, 2020
As an infectious disease and clinical microbiology expert, Prof. Rodney E. Rohde of the Texas State University College of Health Professions receives daily calls from the media, government and university officials, and public health and professional organizations asking him about the emerging novel coronavirus outbreak. In this article, he shares some of the most common questions and his responses.
Read Prof. Rohde's Elsevier Connect article 6 of the most common coronavirus questions the media is asking
Prof. Rohde has also published two nCoV articles with the American Society for Microbiology (ASM):
- 2019 Novel Coronavirus (2019-nCoV) Update: Uncoating the Virus
- Novel Coronavirus Lab Protocols and Responses: Next Steps
Podcast: How long could the coronavirus that causes COVID-19 be with us?
Prof. Rohde talks about the likelihood of this virus extending "beyond this season, beyond this year," per guidance from the CDC.
Interactive map: global disease outbreak experts
The map represents the most active institutions researching disease outbreak and control. We ran a search in Scopus — a source-neutral abstract and citation database of over 75 million records — for publications researching the coronavirus and related diseases such as SARS from 1996 to the present (Feb 6, 2020). We then used the resulting ~22,000 publications to identify the researchers and institutions that are working in these areas. The map shows the 500 most prolific global institutions, along with the 200 most prolific Chinese institutions by publication count.
Click on a pin to see more about the institution, the numbers of researchers and their publications. Then link through to the researcher's profiles in Scopus to learn more about their areas of expertise.
Key facts for clinicians
By Margaret Trexler Hessen, MD, Director, Point of Care, Elsevier | Updated Feb 21, 2020
Background: In December, China notified the World Health Organization of several cases of human respiratory illness, which appeared to be linked to an open seafood and livestock market in the city of Wuhan. The infecting agent has since been identified as a novel coronavirus, now called SARS-CoV-2 (initially called 2019-nCoV). Although the virus is presumed zoonotic in origin, person-to-person spread is evident. Novel Coronavirus associated infection is now designated as COVID-19. Cases have now been reported in many parts of mainland China and in other countries in Asia, Europe, the eastern Mediterranean, Australia, Asia Pacific and North America. Travel within China has been restricted and travel to and from China markedly reduced. Screening of travelers is being implemented in other countries and quarantine measures have been enacted under some circumstances. Despite these precautions, it is anticipated that more cases will be seen both inside China and internationally.
Novel coronaviruses have emerged as human pathogens in the past, notably associated with outbreaks of SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome). Current investigative methods and recommendations derive in some part from the experience of those epidemics.
Clinical presentation: The incubation period is thought to be 2 to 14 days. Symptoms include fever (which may be absent in persons at extremes of age or with immunocompromise), cough and dyspnea. Chest radiographs may show bilateral infiltrates. Clinical illness varies from mild to severe; about 25 percent of confirmed cases have been classified as severe, with up to 32 percent requiring intensive care for respiratory support. Some reports suggest worsening during the second week of illness. In early cases, mortality was associated with advanced age or comorbidities. Asymptomatic infection has also been described.
Diagnosis: Although respiratory infections (including influenza) are prevalent in the northern hemisphere during the winter, clinicians should inquire about travel history in persons presenting with respiratory illness. The possibility of COVID-19 infection should be suspected in persons who present with compatible clinical illness and exposure history. The US Centers for Disease Control (CDC) and World Health Organization (WHO) have slightly different criteria for whom to test, as noted below:
- Recent travel (within 14 days) from Wuhan, Hubei Province, China (WHO). The CDC has broadened geographic criteria to include travel from Hubei Province — and for persons with fever and lower respiratory illness requiring hospitalization, travel from mainland China.
- Close contact with a person suspected or known to have infection due to 2019-nCoV (WHO, CDC). The CDC defines close contact as being within 6 feet (2 meters) or within a room or care area for a prolonged period without personal protective equipment OR having direct contact with secretions of a person with 2019-nCoV infection.
- Exposure to a healthcare facility in a country where hospital-associated nCoV infections have been reported (WHO).
- Disease occurring in a healthcare worker who has been working in an environment where patients with severe acute respiratory infections are being cared for, without regard to place of residence or history of travel (WHO).
- A respiratory infection develops an unusual or unexpected clinical course, especially sudden deterioration despite appropriate treatment, without regard to place of residence or history of travel, even if another etiology has been identified that fully explains the clinical presentation (WHO).
- For patients that are severely ill, evaluation for COVID-19 may be considered even if a known source of exposure has not been identified (CDC).
In the United States, suspected cases should be reported immediately to local or state health departments, which will determine whether the patient meets clinical and epidemiologic criteria for disease and coordinate diagnostic testing of suspected patients through the CDC. Collection of specimens from the upper respiratory tract, lower respiratory tract and serum is recommended as a priority; other specimens, such as stool or urine, may be collected and stored to be tested at the discretion of the CDC. The CDC provides detailed information on collection and shipping of specimens for cases approved by local or state authorities. The CDC advises that testing for other respiratory pathogens by the provider should be done as part of the initial evaluation and should not delay specimen shipping to CDC.
If a patient with suspected COVID-2019 infection tests positive for another respiratory pathogen, after clinical evaluation and consultation with public health authorities, they may no longer be considered a person under investigation.
Management: Patients with a mild clinical presentation may not require hospitalization but should be monitored for worsening, especially in the second week of illness. No specific antiviral agent is available for treatment of this infection, and there is no vaccine. Treatment is supportive and includes supplemental oxygen and conservative fluid management, as indicated by clinical condition. WHO provides detailed guidance on such supportive measures and cautions that severely ill patients should be treated empirically for other possible causes while diagnostic test results are pending.
Infection control measures are an integral part of management:
- Provide the patient with a face mask and place the patient in a closed room (preferably with structural safeguards against airborne transmission).
- Persons entering the room should follow standard, contact, and airborne precautions.
- Patients managed at home are encouraged to self-isolate to a single area of the house (preferably with a separate bathroom) and to wear a face mask during any contact with household members.
- The patient and all household members should follow diligent hand and cough hygiene.
Complications: Respiratory failure and septic shock occur in some patients. The case fatality rate is about 2 percent.
Margaret Trexler Hessen, MD, is an infectious disease specialist with 20 years of clinical practice experience and public health service, including outbreak management. She has been with Elsevier since 2010 and is currently Director, Point of Care.
Clinicians need reliable and current information to combat novel coronavirus
By Jonathan Temte, MD, PhD, Consultant, PracticeUpdate, Elsevier
Coronaviruses are incredibly diverse, found in many animal species, and are commonly encountered in clinical practice during the cold and flu season, yet many primary care clinicians are not familiar with these respiratory pathogens. We rarely test for them, and when we do it’s usually when we’re looking for something else. Moreover, we have no specific treatments for these viruses.
The usual suspects have funny names: coronavirus HKU1, NL63, 229E and OC43. In our ongoing surveillance and epidemiological studies in school, clinics and longterm care settings, we find all four of these. There are two other coronaviruses that have been previously shown to infect humans: SARS (severe acute respiratory syndrome-associated coronavirus, or SARS-CoV), which emerged in 2003, and MERS (Middle East Respiratory Syndrome Coronavirus, or MERS-CoV), which emerged in 2012. SARS and MERS are associated with high case fatality rates.
Now a novel coronavirus, named 2019-nCoV, has emerged in China. There are hundreds of cases in China and multiple cases across the globe. The second case in the US was confirmed Friday in Illinois. We are extremely early in this rapidly expanding outbreak. With this evolving situation comes fear, misinformation and many unknowns. Accordingly, clinicians need to find reliable and current sources of credible information. A good place to start is the CDC resource page for healthcare professionals.
Jonathan Temte, MD, PhD, is Associate Dean for Public Health and Community Engagement and Professor of Family Medicine and Community Health at the University of Wisconsin School of Medicine and Public Health and former Chair of the Advisory Committee on Immunization Practices (ACIP). Jon currently serves as Chair of the Wisconsin Council on Immunization Practices and has been active on pandemic influenza and bioterrorism working groups for the state. He is a consultant for Elsevier's PracticeUpdate.
Elsevier Clinical Solutions
We've selected content from ClinicalKey, Clinical Solutions Nursing, Interprofessional Practice and Patient Education collections to share what we know to date about the novel coronavirus.
Clinical Overviews on ClinicalKey
Clinical Overviews are easy-to-scan clinically focused medical topic summaries designed to match the clinician workflow. Elsevier's Point-of-Care Editorial team develops Clinical Overviews through a process that includes review and revision by a medical editor; peer reviews performed by subject matter experts; a production review to ensure consistency in style, grammar, and punctuation; and a final evaluation by the editor-in-chief.
Clinical Skills for Nursing
Clinical Skills for Nursing provides the highest quality evidence for nursing practice procedures for nurses to care for patients. Our Isolation Precautions and Personal Protective Equipment checklists align with CDC and OSHA guidelines:
- Skills checklist “Isolation Precautions and Personal Protective Equipment”
- Extended text: “Isolation Precautions: Personal Protective Equipment”
- FAQ based the recommendations made by the CDC and WHO for nurses and patients
Interprofessional Care Plans
These Interprofessional Care Plans provide an evidence-based and individualizable Interprofessional plan of care to manage fever and the possible development of pneumonia, which is consistent with the presentation of this virus. Using an interprofessional approach to patient care that aligns current evidence with the individual needs of the patient results in improved patient care outcomes.
- Care Plan Guide: Fever — Adult
- Care Plan Guide: Fever — Pediatric
- Care Plan Guide: Pneumonia — Adult
- Care Plan Guide: Pneumonia — Pediatric
Patient engagement resources
Patient engagement resources use plain language to support shared decision-making between patients and healthcare providers. The goal is to deliver the right message in the right way at the time the patient is most ready to learn. The following resources provide an overview of the novel coronavirus to help patients and their families understand their risk, identify signs and symptoms, and prevent it from spreading:
Video overview of Coronavirus from 3D4Medical - Watch now:
中文资源 (Chinese-language resources)
|Title||Published by (CN)||Published by (EN)||Link|
|2019新型冠状病毒信息库||National Genomics Data Center|
National Microbiological Data Center;|
National Pathogen Resource Collection Center
|Diagnosis & Treatment Guidelines|
|新型冠状病毒感染的肺炎诊疗方案（试行第三版）（PDF可下载）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/yzygj/s7653p/202001/f492c9153ea9437bb587ce2ffcbee1fa.shtml|
|湖北省新型冠状病毒感染的肺炎诊疗方案(试行第一版）||湖北省医疗救治专家组||Medical Expert Panel of Hubei Province||https://xw.qq.com/cmsid/20200123A0KNOW00|
|《新型冠状病毒肺炎诊疗快速指南》||华中科技大学同济医学院附属同济医院专家组||Tongji Hospital, Tongji Medical College of HUST||https://xw.qq.com/health/20200124010910/HLH2020012401091000|
|《武汉协和医院处置2019新型冠状病毒感染策略及说明》||华中科技大学同济医学院附属协和医院专家组||Xiehe Hospital, Tongji Medical College of HUST||https://www.dxy.cn/bbs/newweb/pc/post/42662254|
|关于“新型冠状病毒感染的肺炎”诊疗建议方案（V2.0）||中国医学科学院北京协和医院||Peking Union Medical College Hospital, CAMS||https://new.qq.com/omn/HLH20200/HLH2020012501009300.html|
|医疗机构内新型冠状病毒感染预防与控制技术指南（第一版）||国家卫生健康委员会||National Health Commission|
|新型冠状病毒实验室生物安全指南（第二版）||国家卫生健康委员会||National Health Commission|
|新型冠状病毒感染的肺炎诊疗方案（试行第四版）||国家卫生健康委员会||National Health Commission|
|新型冠状病毒感染的肺炎防控方案（第三版）||国家卫生健康委员会||National Health Commission|
|新型冠状病毒感染的肺炎病例转运工作方案（试行）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/zhengcwj/202001/ccee6ec0942a42a18df8e5ce6329b6f5.shtml|
|新型冠状病毒感染的肺炎患者遗体处置工作指引（试行）||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/yzygj/s7659/202002/163c26a24057489dbf64dba359c59a5f.shtml|
|新型冠状病毒感染的肺炎疫情分布||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention|
|Research articles and book chapters|
|Notes from the Field: An Outbreak of NCIP (2019-nCoV) Infection in China — Wuhan, Hubei Province...[2020-01-22]||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/e3c63ca9-dedb-4fb6-9c1c-d057adb77b57|
|A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases — Wuhan, China 2019-2020[2020-01-21]||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/en/article/id/a3907201-f64f-4154-a19e-4253b453d10c|
|中国新型冠状病毒感染病例首批临床数据报告（解读,||The Lancet Weichat Official Account||The Lancet Weichat Official Account||https://marlin-prod.literatumonline.com/pb-assets/Lancet/marketing/wechat/WeChat_website.jpg|
|引自《默里及纳达尔呼吸医学》，V Courtney Broaddus 主编，李为民、程德云主译，人民卫生出版社，2018||李为民、程德云主译，人民卫生出版社，2018||Elsevier, with content quoted from translation published by PMPH|
|轻症疑似2019新型冠状病毒患者及密切接触人员如何进行自我管理||北京协和医院呼吸科||Respiratory Department, Peking Union Medical College Hospital, CAMS||http://m.sohu.com/a/368777653_102327|
|《新型冠状病毒感染防护》||Elsevier Clinical Solutions||新型冠状病毒感染防护》|
|Institutional Special Reports|
|国家卫生健康委员会新型冠状病毒感染的肺炎专题||国家卫生健康委员会||National Health Commission||http://www.nhc.gov.cn/xcs/xxgzbd/gzbd_index.shtml|
|中国疾病预防控制中心新型冠状病毒感染的肺炎专题||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://www.chinacdc.cn/jkzt/crb/zl/szkb_11803/|
|中国疾病预防控制中心周报（English Version）||中国疾病预防控制中心||Chinese Center for Disease Control and Prevention||http://weekly.chinacdc.cn/|
|Key Media Special Reports|
|抗击肺炎专题||今日头条||Beijing Byte Dance Technology Co., Ltd.||https://www.toutiao.com/|
|#我在疫情第一线#||三联生活周刊||Sanlian Life Weekly||https://s.weibo.com/weibo?q=%23%E6%88%91%E5%9C%A8%E7%96%AB%E6%83%85%E4%B8%80%E7%BA%BF%23&from=default|
- 3D4Medical的旗舰平台Complete Anatomy，是世界上最先进的解剖学平台。2019年注册用户超过了120万，有超过2500万的下载量，在160个国家的苹果、微软和谷歌的应用商店中被选为排名第一的医疗应用。
In this section, you can find the following resources:
- Journal articles, including The Lancet Coronavirus hub
- Book chapters
- Early-stage research (preprints on SSRN)
- Resources for drug discovery
To assist health workers and researchers working under difficult and dangerous conditions to bring this outbreak to a close, The Lancet has created a Coronavirus hub page. This hub brings together new coronavirus content from The Lancet journals as it is published.
At Cell Press, we recognize the urgent need to quickly share information that can help us better understand the biology of the SARS-CoV-2 coronavirus (COVID-19) as well as produce a potential vaccine. On our Coronavirus Resource Hub, curated by members of our editorial team, you'll find our policies for submitting papers related to COVID-19, as well as content about the outbreak as it appears in Cell Press journals. Visit our hub
1science, acquired by Elsevier in 2018, was created to expand the scope of existing abstracting and analytics databases. It aims to include quality controlled academic and research documents in all disciplines and languages and from all countries. Its core index, 1findr, currently comprises more than 120 million metadata records, including over 30 million links to free full-text articles selected from about 100,000 referred scholarly journals.
The Coronavirus Research Repository is a custom extraction from 1findr comprising articles on COVID-19, MERS, SARS and coronaviruses in general.
Content hubs from other publishers
Elsevier is among various publishers who are making relevant papers freely available. Others include: Springer Nature | Wiley | NEJM | BMJ | American Society for Microbiology | Chongqing VIP Information
Many publishers have also signed the Wellcome Trust Statement committing to share relevant nCoV research and data rapidly and openly.
Articles in Elsevier journals
Below are a selection of articles curated by our clinical solutions team and directly relevant to Novel Coronavirus (2019-nCov).
In addition to these, Elsevier has made more than 2,500 coronavirus-related articles freely available for the next six months (commencing 10/02/2019). You can find these articles here.
We will be updating this section continually.
- Integrated infection control strategy to minimize nosocomial infection of corona virus disease 2019 among ENT healthcare workers, Letter to the Editor, Journal of Hospital Infection (Feb 27, 2020)
- COVID-19 in medical personnel: observation from Thailand, Letter to the Editor, Journal of Hospital Infection (Feb 27, 2020)
- The non-contact handheld cutaneous infra-red thermometer for fever screening during the COVID-19 global emergency, Letter to the Editor, Journal of Hospital Infection (Feb 21, 2020)
- Novel coronavirus pneumonia emergency in Zhuhai: impact and challenges, Letter to the Editor, Journal of Hospital Infection (Feb 14, 2020)
- Novel coronavirus, poor quarantine, and the risk of pandemic, Opinion, Journal of Hospital Infection (Feb 11, 2020)
- Novel coronavirus is putting the whole world on alert, Opinion, Journal of Hospital Infection (Feb 4, 2020)
- First Atypical case of 2019 novel coronavirus in Yan'an, China, Letter to the Editor, Clinical Microbiology and Infection (Feb 20, 2020)
- Novel coronavirus: how things are in Wuhan, Commentary, Clinical Microbiology and Infection (Feb 11, 2020)
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges, International Journal of Microbial Agents (Feb 17, 2020)
- Chloroquine for the 2019 novel coronavirus SARS-CoV-2, International Journal of Microbial Agents (Feb 15, 2020)
- Trend and forecasting of the COVID-19 outbreak in China, Letter to the Editor, Journal of Infection (Feb 27, 2020)
- Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China, Journal of Infection (Feb 25, 2020)
- Characteristics of COVID-19 infection in Beijing, Journal of Infection (Feb 25, 2020)
- Recent insights into 2019-nCoV: a brief but comprehensive review, Journal of Infection (Feb 25, 2020)
- Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests, Short Communication, International Journal of Infectious Diseases (Feb 27 2020)
- Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2), Journal of Integrative Medicine (Feb 19, 2020)
- Novel coronavirus (2019-nCoV) cases in Hong Kong and implications for further spread, Journal of Infection (Feb 22, 2020)
- Clinical and computed tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2, Journal of Infection (Feb 25, 2020)
- 2019-novel Coronavirus severe adult respiratory distress syndrome in two cases in Italy: An uncommon radiological presentation, International Journal of Infectious Diseases (Feb 26 2020)
- First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan, Journal of the Formosan Medical Association (Feb 26, 2020)
- Should, and how can, exercise be done during a coronavirus outbreak? An interview with Dr. Jeffrey A. Woods, Journal of Sport and Health Science (March 2020)
- Coronavirus disease (COVID-19): The need to maintain regular physical activity while taking precautions, Opinion, Journal of Sport and Health Science (March 2020)
- Technical guidance for laboratory testing of 2019-nCoV infection (third edition). Biosafety and Health (Feb 5, 2020)
- A strategy to prevent future epidemics similar to the 2019-nCoV outbreak, Biosafety and Health (Feb 5, 2020)
- In silico screening of Chinese herbal medicines with the potential to directly inhibit 2019 novel coronavirus, Journal of Integrative Medicine (Feb 20, 2020)
- A Systematic Review of therapeutic agents for the treatment of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Travel Medicine and Infectious Diseases (July 2019)
- Asymptomatic Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: Extent and implications for infection control: A systematic review, Travel Medicine and Infectious Diseases (January 2019)
- A strategy to prevent future epidemics similar to the 2019-nCoV outbreak, Biosafety and Health (Feb 5, 2020)
- Laboratory biosafety guide for the novel coronavirus, Biosafety and Health (Jan 31, 2020)
- Coronavirus Outbreak: What the Department of Radiology Should Know, Journal of the American College of Radiology (Feb 19, 2020)
- Coronavirus Disease 2019: Coronaviruses and Blood Safety, Transfusion Medicine Reviews (Feb 21, 2020)
- Airborne bacterial contaminations in typical Chinese wet market with live poultry trade, Science of the Total Environment (Dec 2016)
- Nutraceuticals have potential for boosting the type 1 interferon response to RNA viruses including influenza and coronavirus, Progress in Cardiovascular Diseases (Feb 12, 2020)
- Lessons learned from the 2019-nCoV epidemic on prevention of future infectious diseases, Microbes and Infection (Feb 20, 2020)
- The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future, Microbes and Infection (Feb 20, 2020)
- Novel coronavirus: From discovery to clinical diagnostics, Opinion, Infection, Genetics and Evolution (April 2020)
- Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event, Short communication, Infection, Genetics and Evolution (April 2020)
- Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China, Microbes and Infection (Feb 2020)
- Pathogenicity and Transmissibility of 2019-nCoV—A Quick Overview and Comparison with Other Emerging Viruses, Microbes and Infection (Feb 2020)
- The Middle East Respiratory Syndrome (MERS), Infectious Disease Clinics of North America (Dec 2019)
- Severe Acute Respiratory Syndrome: Historical, Epidemiologic, and Clinical Features, Infectious Disease Clinics of North America (Dec 2019)
- Human Mobility and the Global Spread of Infectious Diseases: A Focus on Air Travel, Trends in Parisitology (Sept 2018)
- Biothreat Agents and Emerging Infectious Disease in the Emergency Department, Emergency Medicine Clinics of North America (May 2019)
- Emerging Respiratory Viruses in Children, Infectious Disease Clinics of North America (March 2018)
- Betacoronavirus Adaptation to Humans Involved Progressive Loss of Hemagglutinin-Esterase Lectin Activity, Cell Host & Microbe (March 2017)
- Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome), Clinics in Chest Medicine (March 2017)
- The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, China, International Journal of Infectious Diseases (Feb 2020)
- Cross-sectional investigation and risk factor analysis of community-acquired and hospital-associated canine viral infectious respiratory disease complex, Heliyon (Nov 2019)
- Chiral zirconium quantum dots: A new class of nanocrystals for optical detection of coronavirus, Heliyon (Aug 2018)
- MERS-CoV as an emerging respiratory illness: A review of prevention methods, Travel Medicine and Infectious Disease (January 2020)
- The association between domestic train transportation and novel coronavirus (2019-nCoV) outbreak in China from 2019 to 2020: A data-driven correlational report, Travel Medicine and Infectious Disease (January 2020)
- The next big threat to global health? 2019 novel coronavirus (2019-nCoV): What advice can we give to travellers? – Interim recommendations January 2020, from the Latin-American society for Travel Medicine (SLAMVI) Travel Medicine and Infectious Disease (January 2020)
- SARS-CoV, MERS-CoV and now the 2019-novel CoV: Have we investigated enough about coronaviruses? – A bibliometric analysis, Travel Medicine and Infectious Disease (January 2020)
- Prospect and application of Internet of Things technology for prevention of SARIs, Clinical eHealth (February 2020)
- Middle East Respiratory Syndrome Coronavirus: What Do We Know?, The Journal for Nurse Practitioners (Jan 2015)
More published research
- Positive RT-PCR Test Results in Patients Recovered From COVID-19, Research Letter, JAMA (Feb 27, 2020)
- Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection, Journal of Medical Virology (Feb 26, 2020)
- Chest Radiographic and CT Findings of the 2019 Novel Coronavirus Disease (COVID-19): Analysis of Nine Patients Treated in Korea, Korean Journal of Radiology (Feb 26, 2020)
- Emergent Strategies for the Next Phase of COVID-19, Infection & Chemotherapy (Feb 25, 2020)
- 18F-FDG PET/CT findings of COVID-19: a series of four highly suspected cases, European Journal of Nuclear Medicine and Molecular Imaging (Feb 22, 2020)
- Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection, Radiology (Feb 20, 2020)
- Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series, BMJ (Feb 19, 2020)
- Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020, Emerging Infectious Diseases (May 17, 2020).
- Covid-19: surge in cases in Italy and South Korea makes pandemic look more likely, BMJ (Feb 25, 2020)
- Angel N. Desai, MD, PhD: Discussing the ABCs of Health Security—Antibiotic Resistance, Biothreats, and Coronavirus, Medical News & Perspectives, JAMA (Feb 19, 2020)
- Real-time forecasts of the COVID-19 epidemic in China from February 5th to February 24th, 2020, Infectious Disease Modelling, Feb 2020
- IDM editorial statement on the 2019-nCoV, Infectious Disease Modelling, Feb 2020
- An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov), Infectious Disease Modelling, Feb 2020
- Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of Extracorporeal Membrane Oxygenation, Viewpoint, JAMA (Feb 19, 2020)
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China, JAMA (Feb 7, 2020)
- Emerging Coronavirus 2019-nCoV Pneumonia, Radiology (Feb 6, 2020)
- Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus, World Journal of Pediatrics (Feb 5, 2020)
- Imaging changes in patients with 2019-nCov, European Radiology (Feb 5, 2020)
- Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China, Intensive Care Medicine (Feb 5, 2020)
- History is repeating itself: Probable zoonotic spillover as the cause of the 2019 novel Coronavirus Epidemic, Editorial, Le Infezioni in Medicina (March 5, 2020)
- Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern, Editorial, Eurosurveillance (Feb 6, 2020)
- 2019 Novel Coronavirus—Important Information for Clinicians, Viewpoint, JAMA Network (Feb 5, 2020)
- Chest CT Findings in 2019 Novel Coronavirus (2019-nCoV) Infections from Wuhan, China: Key Points for the Radiologist, Reviews and Commentary Editorial, Radiology (Feb 4, 2020)
- CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV), Case Series, Radiology (Feb 4, 2020)
- A pneumonia outbreak associated with a new coronavirus of probable bat origin, unedited manuscript, Nature (Feb 3, 2020)
- First Case of 2019 Novel Coronavirus in the United States, The New England Journal of Medicine (Jan 31, 2020)
- Vincent J. Munster, PhD, et al: A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment, The New England Journal of Medicine (Jan 24, 2020)
- Na Zhu, PhD, et al: A Novel Coronavirus from Patients with Pneumonia in China, 2019, The New England Journal of Medicine (Jan 24, 2020)
- Stanley Perlman, MD, PhD: Another Decade, Another Coronavirus, The New England Journal of Medicine (Jan 24, 2020)
- Catharine I. Paules, MD; Hilary D. Marston, MD, MPH; Anthony S. Fauci, MD: Coronavirus Infections — More Than Just the Common Cold – JAMA Viewpoint, JAMA (Jan 2020)
- Novel Coronavirus from Wuhan China, 2019-20, Update to Chapter 155, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Ninth Edition (Elsevier, 2020)
- Coronaviruses, Including Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS), Chapter 155, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, Ninth Edition (Elsevier, 2020)
- Viral Infections, Chapter 32, Murray and Nadel’s Textbook of Respiratory Medicine, Sixth Edition (Elsevier, 2016)
- Coronaviruses, Chapter 31, Fenner and White's Medical Virology (Fifth Edition (Elsevier's Academic Press, 2017)
Early-stage research (preprints on SSRN platform)
Emerging and rapidly evolving healthcare emergencies necessitate the quick dissemination of research. The growing role of preprints, or early-stage research, was acknowledged in the Ebola and Zika virus outbreaks as a way of “accelerating the dissemination of scientific findings to support responses to infectious disease outbreaks.”
SSRN, Elsevier’s world-leading platform devoted to the rapid worldwide dissemination of early-stage research, is committed to making authors' coronavirus related research available immediately. Research on SSRN is free to download and upload. It is important to note that these papers have not benefited from the pivotal role of the peer-review process, which validates and improves the quality of final published journal articles.
- Probable Pangolin Origin of 2019-nCoV Associated with Outbreak of COVID-19, Cell Press Sneak Peak (Feb 28, 2020)
- ACP Risk Grade: A Simple Mortality Index for Patients with Confirmed or Suspected Severe Acute Respiratory Syndrome Coronavirus 2 Disease (COVID-19) During the Early Stage of Outbreak in Wuhan, China, Preprints with The Lancet (Feb 28, 2020)
- Clinical Characteristics of 24 Asymptomatic Infections with COVID-19 Screened Among Close Contacts in Nanjing, China, Preprints with The Lancet (Feb 28, 2020)
- Epidemiological and Clinical Characteristics of 124 Elderly Outpatients with COVID-19 in Wuhan, China, Preprints with The Lancet (Feb 28, 2020)
- Current Situation of the Corona Virus Disease Under Active Control and Prevention in China, Outside Hubei Province: A Real-World Epidemiological Analysis, Preprints with The Lancet (Feb 28, 2020)
- Epidemiological Benchmarks of the COVID-19 Outbreak Control in China After Wuhan's Lockdown: A Modelling Study with an Empirical Approach, Preprints with The Lancet (Feb 28, 2020)
- Phase- and Epidemic Regions- Adjusted Estimation of the Number of Coronavirus Disease 2019 Cases in China, Preprints with The Lancet (Feb 28, 2020)
- Characteristics of Pulmonary Auscultation in Patients with 2019 Novel Coronavirus in China, Preprints with The Lancet (Feb 28, 2020)
- Conjunctival Polymerase Chain Reaction-Tests of 2019 Novel Coronavirus in Patients in Shenyang, China, Preprints with The Lancet (Feb 28, 2020)
- The Spatiotemporal Estimation of the Dynamic Risk and the International Transmission of 2019 Novel Coronavirus (COVID-19) Outbreak: A Global Perspective, Preprints with The Lancet (Feb 28, 2020)
- Clinical Characteristics of 457 Cases with Coronavirus Disease 2019, Preprints with The Lancet (Feb 28, 2020)
- Protection of 318 Inflammatory Bowel Disease Patients from the Outbreak and Rapid Spread of COVID-19 Infection in Wuhan, China, Preprints with The Lancet (Feb 27, 2020)
- Ocular Dectection of SARS-CoV-2 in 114 Cases of COVID-19 Pneumonia in Wuhan, China: An Observational Study, Preprints with The Lancet (Feb 27, 2020)
- Artificial Intelligence Application in COVID-19 Diagnosis and Prediction, Preprints with The Lancet (Feb 27, 2020)
- Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study, Preprints with The Lancet (Feb 25, 2020)
- Candidate Targets for Immune Responses to 2019-Novel Coronavirus (nCoV): Sequence Homology- and Bioinformatic-Based Predictions, Cell Press Sneak Peak (Feb 25, 2020)
- Epidemic Characteristics of 2019-nCoV in China, Jan 23, 2020-Feb 11, 2020, Preprints with The Lancet (Feb 25, 2020)
- COVID-19 Epidemic: How Is the Depression of People Staying in Wuhan and People Leaving Wuhan? A Cross-Sectional Study, Preprints with The Lancet (Feb 25, 2020)
- Survey of Insomnia and Related Social Psychological Factors Among Medical Staffs Involved with the 2019 Novel Coronavirus Disease Outbreak, Preprints with The Lancet (Feb 25, 2020)
- Trend and Forecasting of the COVID-19 Outbreak in China, Preprints with The Lancet (Feb 25, 2020)
- Clinical Outcomes of Patients with 2019-nCoV: A Preliminary Summary, Preprints with The Lancet (Feb 25, 2020)
- 2019-nCoV Pneumonia in a Normal Work Infectious Diseases Hospital Besides Hubei Province, China, Preprints with The Lancet (Feb 25, 2020)
- Transmission of 2019-nCoV to Health-Care Workers in the Early Epidemic, Preprints with The Lancet (Feb 25, 2020)
- Analysis of 2019-nCoV Infection and Clinical Manifestations of Outpatients: An Epidemiological Study from the Fever Clinic in Wuhan, China, Preprints with The Lancet (Feb 25, 2020)
- The Ongoing Epidemic of 2019 Novel Coronavirus (SARS-CoV-2): Infection and Fatality Trends in Wuhan, Hubei and Across China, Preprints with The Lancet (Feb 25, 2020)
- Estimation of the Epidemic Properties of the 2019 Novel Coronavirus: A Mathematical Modeling Study, Preprints with The Lancet (Feb 25, 2020)
- Epidemic Growth and Reproduction Number for the Novel Coronavirus Disease (COVID-19) Outbreak on the Diamond Princess Cruise Ship from January 20 to February 19, 2020: A Preliminary Data-Driven Analysis (Feb 24, 2020)
- SARS-CoV-2 Infection Does Not Significantly Cause Acute Renal Injury: An Analysis of 116 Hospitalized Patients with COVID-19 in a Single Hospital, Wuhan, China, Preprints with The Lancet (Feb 24, 2020)
- Characteristics of Peripheral Lymphocyte Subset Alteration in 2019-nCoV Pneumonia, Preprints with The Lancet (Feb 24, 2020)
- Clinical and Imaging Evidence of Wuhan-Viral Pneumonia: A Large-Scale Prospective Cohort Study, Preprints with The Lancet (Feb 21, 2020)
- Statistical Estimate of Epidemic Trend, Suggestions and Lessons for Public Safety from the 2019 Novel Coronavirus (COVID-19), Preprints with The Lancet (Feb 21, 2020)
- Epidemic Trend and Transmission Risk of SARS-CoV-2 after Government Intervention in the Mainland of China: A Mathematical Model Study, Preprints with The Lancet (Feb 20,2020)
- Dynamics of the Latest 2019 Novel Coronavirus Disease Epidemic in China: A Descriptive Study, Preprints with The Lancet (Feb 20,2020)
- Clinical Characteristics Predicting Progression of COVID-19, Preprints with The Lancet (Feb 20,2020)
- Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources (Feb 20, 2020)
- Clinical Characteristics and Treatment of Patients Infected with COVID-19 in Shishou, China, Preprints with The Lancet (Feb 20, 2020)
- Characteristics of COVID-19 Infection In Beijing, Preprints with The Lancet (Feb 20, 2020)
- Perceived Social Support and Its Impact on Psychological Status and Quality of Life of Medical Staffs After Outbreak of SARS-CoV-2 Pneumonia: A Cross-Sectional Study, Preprints with The Lancet (Feb 20, 2020)
- Clinical Characteristics of 60 COVID-19-Infected Patients with or Without Renal Injury In Hangzhou, China, Preprints with The Lancet (Feb 20, 2020)
- The Epidemiologic and Clinical Features of Suspected and Confirmed Cases of Imported 2019 Novel Coronavirus Pneumonia in North Shanghai, China, Preprints with The Lancet (Feb 20, 2020)
- Analysis of 2019 Novel Coronavirus Infection and Clinical Characteristics of Outpatients: An Epidemiological Study from the Fever Clinic in Wuhan, China, Preprints with The Lancet (Feb 20, 2020)
- Clinical Characteristics of 5732 Patients with 2019-nCoV Infection, Preprints with The Lancet (Feb 20, 2020)
- Evaluating Incidence and Impact Estimates of the Coronavirus Outbreak from Official and Non-Official Chinese Data Sources (Feb 20, 2020)
- The Role of Angiotensin Converting Enzyme 2 in Coronaviruses/Influenza Viruses and Cardiovascular Disease, Preprints with The Lancet (Feb 19, 2020)
- Estimation of the Time-Varying Reproduction Number of COVID-19 Outbreak in China, Preprints with The Lancet (Feb 19, 2020)
- Epidemiological and Clinical Features of 197 Patients Infected with 2019 Novel Coronavirus in Chongqing, China: A Single Center Descriptive Study, Preprints with The Lancet (Feb 19, 2020)
- Longitudinal Characteristics of Lymphocyte Responses and Cytokine Profiles in the Peripheral Blood of SARS-CoV-2 Infected Patients, Preprints with The Lancet (Feb 19, 2020)
- Rapid Detection of Novel Coronavirus (COVID19) by Reverse Transcription-Loop-Mediated Isothermal Amplification, Preprints with The Lancet (Feb 19, 2020)
- The Risk of Death in 2019 Novel Coronavirus Disease (COVID-19) in Hubei Province, Preprints with The Lancet (Feb 19, 2020)
- Utilize State Transition Matrix Model to Predict the Novel Corona Virus Infection Peak and Patient Distribution, Preprints with The Lancet (Feb 19, 2020)
- The Laboratory Tests and Host Immunity of 2019 Novel Coronavirus-Infected Patients with Different Severity of Illness in Tongji Hospital, Wuhan, China, Preprints with The Lancet (Feb 19, 2020)
- The Clinical Characteristics of Myocardial Injury in Severe and Very Severe Patients with 2019 Novel Coronavirus Disease, Preprints with The Lancet (Feb 19, 2020)
- Clinical and High-Resolution CT Features of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pneumonia: Comparison of the Initial and Follow-Up Changes, Preprints with The Lancet (Feb 19, 2020)
- Reverse Logistics Network Design for Effective Management of Medical Waste in Epidemic Outbreak: Insights from the Coronavirus Disease 2019 (COVID-19) in Wuhan (Feb 18, 2020)
- The Psychological Impact of Quarantine and How to Reduce It: Rapid Review of the Evidence, Preprints with The Lancet (Feb 6, 2020)
- Clinical Features of 2019 Novel Coronavirus Pneumonia Presented Gastrointestinal Symptoms But Without Fever Onset, Preprints with The Lancet (Feb 6, 2020)
- Transmission Dynamics of 2019 Novel Coronavirus (2019-nCoV), Preprints with The Lancet (Feb 5, 2020)
- Understanding Unreported Cases in the 2019-Ncov Epidemic Outbreak in Wuhan, China, and the Importance of Major Public Health Interventions, Preprints with The Lancet (Feb 4, 2020)
- Epidemic Prediction of 2019-nCoV in Hubei Province and Comparison with SARS in Guangdong Province, Preprints with The Lancet (Feb 4, 2020)
- An Evidence-Based Framework for Priority Clinical Research Questions for 2019-nCoV, Preprints with The Lancet (Feb 4, 2020)
- The Epidemic Dynamics of 2019 Novel Coronavirus (2019-nCoV) Infections in China by 28 January, Preprints with The Lancet (Feb 4, 2020)
- Estimating the Number of 2019 Novel Coronavirus Cases in Chinese Mainland, Preprints with The Lancet (Feb 4, 2020)
- From SARS-CoV to Wuhan 2019-nCoV Outbreak: Similarity of Early Epidemic and Prediction of Future Trends, Cell Press Sneak Peak (Jan 31, 2020)
- Cell Pyroptosis, a Potential Pathogenic Mechanism of 2019-nCoV Infection (Jan 29, 2020)
- Estimation of the Transmission Risk of 2019-nCov and Its Implication for Public Health Interventions (Jan 27, 2020)
- Early transmissibility assessment of a novel coronavirus in Wuhan, China (Jan 27, 2020)
- Epidemiological and Clinical Characteristics of 99 Cases of 2019-Novel Coronavirus (2019-nCoV) Pneumonia in Wuhan, China, Preprints with The Lancet (Jan 27, 2020)
- Clinical Characteristics and Vertical Transmission Potential of 2019-nCoV Infection in Patients with Pregnancy, Preprints with The Lancet (Feb 11, 2020)
- Clinical Features and Computed Tomographic Manifestations of Patients with 2019 Novel Coronavirus Pneumonia: A Single Center Study in Shanghai, China, Preprints with The Lancet (Feb 11, 2020)
- Early in the Epidemic: Impact of Preprints on Global Discourse of 2019-nCOV Transmissibility (Feb 12, 2020)
- Nowcasting and Forecasting the Spreading of Novel Coronavirus 2019-nCoV and Its Association with Weather Variables in 30 Chinese Provinces: A Case Study, Preprints with The Lancet (Feb 13, 2020)
- The Evolution of Quarantined and Suspected Cases Determines the Final Trend of the 2019-nCoV Epidemics Based on Multi-Source Data Analyses, Preprints with The Lancet, (Feb 13,2020)
- Novel Coronavirus (2019-nCoV) Outbreak; A Systematic Review for Published Papers, Preprints with The Lancet (Feb 13, 2020)
- Review of Health Security Capacities in Light of 2019-nCoV Outbreak – Opportunities for Strengthening IHR (2005) Implementation, Preprints with The Lancet (Feb 13, 2020)
- Simulating the Infected Population and Spread Trend of 2019-nCov Under Different Policy by EIR Model, Preprints with The Lancet, (Feb 13 2020)
- Correlation Analysis of the Population Emigration Rate in Wuhan and the Trend of Novel Pneumonia in Hubei Province, Preprints with The Lancet, (Feb 13 2020)
- The Epidemiological and Clinical Characteristics of 2019 Novel Coronavirus Infection in Changsha, China, Preprints with The Lancet (Feb 13 2020)
Resources for drug discovery
Elsevier's R&D solutions for pharma and life sciences integrate data, analytics and technology to help researchers make data-driven drug discovery and development decisions and streamline literature monitoring for pharmacovigilance. Here, we will use those tools to generate information relevant to combatting 2019-nCoV.
- 121 drugs and natural products successfully used against previous coronavirus infections including SARS. This list was generated using Elsevier's Pathway Studio.
- 393 substances that interact with 25 targets related to 6 target species including SARS coronavirus, Middle East respiratory syndrome coronavirus, human Middle East respiratory syndrome coronavirus, Human coronavirus 229E, Coronaviridae and Coronavirinae, with normalized affinity value > 6. This list was generated using Elsevier’s Reaxys Medicinal Chemistry.
- Autophagy is a cellular recycling process, whereby cells eliminate damaged or diseased components in order to regenerate and build new healthier cells; thus, viruses are usually identified and disposed of in this way. Would it be possible to induce the autophagy process and limit the viral infection by using some substances? Pathway Studio provides a list of 406 compounds that have been reported inhibiting autophagy pathway, and their related references as well as a list of 802 compounds that have activating roles in autophagy.
- Interactive map shows global spread of the virus (Johns Hopkins CSSE)
- Guidance for businesses and employers (CDC)
- Infection prevention and control for the care of patients with nCoV in healthcare settings (European CDC)
- Flowchart to Identify and Assess 2019 Novel Coronavirus (CDC)
- Travel precautions (CDC)
- Information and updates (CDC)
- Guidance for healthcare professionals (CDC)
- Information for Laboratories (CDC)
- Novel coronavirus advice for the public (WHO)
- Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim Guidance (WHO)
- WHO: Statement on the meeting of the IHR (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV)
- National Genomic Data Center (China) 2019 nCoV Resource Center (新型冠状病毒信息库)
Official coronavirus guidance from various countries:
- Sources of updated information in the EU/EEA countries
- Panamerican Health Organization (Latin American branch of the WHO)
In the media
- NIH clinical trial of remdesivir to treat COVID-19 begins, NIH (Feb 25, 2020) Study enrolling hospitalized adults with COVID-19 in Nebraska.
- CDC expects ‘community spread’ of coronavirus, as top official warns disruptions could be ‘severe,’ STAT (Feb 25, 2020)
- Coronavirus concerns trigger global run on supplies for health workers, causing shortages, STAT (Feb 7, 2020)
- Bill & Melinda Gates Foundation will commit up to $100 million for novel coronavirus response (Feb 5, 2020)
- US expands use of covonavirus diagnostic test, FDA (Feb 4, 2020)
- WHO declares coronavirus outbreak a global health emergency, STAT (Jan 30, 2020)
- Coronavirus Hits China Exchange Programs, Inside Higher Ed (Jan 29, 2020) Following CDC guidance, colleges are suspending travel to China, a popular destination for faculty and students and a country where many colleges have deep connections.